Setmelanotide for weight loss in pseudohypoparathyroidism type 1a
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an experimental medication called setmelanotide to see if it can help with weight loss in people who have pseudohypoparathyroidism type 1a (PHP1a), a rare genetic condition that often leads to obesity. The goal is to find a new treatment option for weight problems related to PHP1a.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pseudohypoparathyroidism type 1a (PHP1a) with a known GNAS gene mutation.
- Your diabetes and high cholesterol are well managed with current treatments.
- You have not changed or started any medications that could affect weight or metabolism in the last 3 months.
- You do not expect to need changes to your medications during the initial treatment period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This trial tests two new medicines, alone or together, to see if they help with weight loss and blood sugar control in adults who have type 2 diabetes and are overweight or have obesity.
This study tests a new medicine to see how well it helps people with excess body weight lose weight. It may be an option if you have tried to lose weight through dieting before but haven't had lasting success.
This study tests an investigational medicine to help people who have lost weight keep it off. It's for adults without diabetes who haven't used similar weight-loss drugs before.
This trial tests the safety and effectiveness of tirzepatide, a once-weekly injection, for weight loss in people with obesity. It might be an option if you have a BMI of 27 or higher with weight-related health problems, or a BMI of 35 or higher, and live in or near Asunción, Paraguay.
This study tests a GLP-1 receptor agonist (a type of medicine that helps with weight and metabolism) in people with polycystic kidney disease who are overweight. It aims to see if this drug can help slow kidney disease progression.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.